Document:

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE
EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY
TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.

 

BONE
BIOLOGICS, CORP.

 

CONVERTIBLE
PROMISSORY NOTE

 

	$3,659,328	September
    19, 2014

 

SECTION
1. General. For value received, BONE BIOLOGICS,
CORP., a Delaware corporation (the “Maker”), hereby promises to pay to MUSCULOSKELETAL TRANSPLANT FOUNDATION,
INC., a District of Columbia non-profit corporation, or its successors/assigns, the principal amount of Three Million Six
Hundred Fifty Nine Thousand Three Hundred and Twenty Eight Dollars ($3,659,328), payable on the Maturity Date (as hereinafter
defined) (subject to prepayment in whole or in part in the manner provided in Section 3 hereof), in such coin or currency of the
United States of America as at the time of payment shall be legal tender therein for the payment of public and private debts;
and, to pay interest on the unpaid balance of the principal amount hereof from the date hereof at a rate equal to eight and one-half
percent (8.5%) per annum, compounded annually, in like coin or currency, together with payment of the principal hereunder, and
to pay interest at such rate on any overdue principal and (to the extent permitted by law) on any overdue interest, from the due
date hereof until the obligation of the Maker with respect to the payment thereof shall be discharged; all payments and prepayments
of principal of this Note and all payments of the interest on this Note to be made at 125 May Street, Suite 300, Edison, New Jersey
08837, or such other location as shall be specified in writing by the holder of this Note to the Maker.

 

SECTION
2. Definitions. As used herein, the following terms
shall have the following respective meanings:

 

The
term “Affiliate” shall mean any person who is a director or officer of the subject referenced or is a person
or entity which directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control
with the subject referenced; and, for purposes of the foregoing, the term “control” shall mean the possession,
directly or indirectly of the power to direct or cause the direction of the management and policies of a party, whether through
the ownership of voting securities, by contract or otherwise.

 

The
term “Common Stock” shall mean shares of the common stock, $0.001 par value, of the Maker as constituted on
the Issuance Date (including any stock into which it may be changed, reclassified or converted).

 

The
term “Conversion Price” shall have the meaning set forth in Section 7.1 hereof.

 

    	1

    	 

    

  

The
term “Conversion Rights” shall have the meaning set forth in Section 7 hereof.

 

The
term “Convertible Securities” shall have the meaning set forth in Paragraph (b) of Section 7.5 hereof.

 

The
term “Equity Securities” shall have the meaning set forth under Rule 405 (or any successor rule) promulgated
by the United States Securities and Exchange Commission under the Securities Act, whether or not said act applies to the Maker
or its securities.

 

The
term “Event of Default” shall have the meaning set forth in Section 6 hereof.

 

The
term “Excluded Shares” shall have the meaning set forth in Paragraph (a) of Section 7.5 hereof.

 

The
term “Issuance Date” shall mean the date first set forth in this Note.

 

The
term “Maker” shall mean Bone Biologics, Corp., a Delaware corporation, the maker of this Note, and shall also
mean any successor Maker which shall become such in the manner prescribed in Section 5 hereof.

 

The
term “Maturity Date” shall mean March 31, 2015.

 

The
term “Next Equity Financing” shall mean a private placement of Equity Securities of the Company in an amount
up to $10,000,000.

 

The
term “New Note” shall have the meaning set forth in Section 7.2 hereof.

 

The
term “Note” shall mean this Note and any Note executed and delivered by the Maker in exchange or replacement
for this Note pursuant to Section 8 hereof.

 

The
term “Options” shall have the meaning set forth in Paragraph (b) of Section 7.5 hereof.

 

The
term “Purchase Agreement” shall mean the Convertible Note Purchase Agreement dated even date herewith between
the Maker and Musculoskeletal Transplant Foundation, Inc.

 

The
term “Securities Act” shall mean the Securities Act of 1933, as amended.

 

The
term “Subject Valuation” shall mean the quotient obtained by dividing (x) the subscription price per share
or other unit of the principal Equity Security sold or to be sold in the Next Equity Financing (calculated on the basis of the
same subscription price payable by investors generally) by (y) the number of shares of Common Stock with respect to which
such share or other unit is then or will become exercisable, convertible or exchangeable, as the case may be.

 

    	2

    	 

    

  

The
term “Subsidiary” shall mean: (x) any present or future Maker at least a majority of the outstanding voting
stock of which shall at the time be owned, directly or indirectly through Subsidiaries, by the Maker, or which is otherwise controlled
by the Maker, and (y) any partnership, association, joint venture or other entity in which the Maker, directly or indirectly,
through Subsidiaries, has a 50% or more equity interest at the time or which is otherwise controlled by the Maker. For purposes
hereof, outstanding voting stock shall be deemed to be capital stock of any class or classes, however designated, having ordinary
voting power for the election of the members of the board of directors or other governing body of such Maker.

 

SECTION
3. Optional Prepayment. The Maker shall have the right
at any time prior to the Maturity Date to prepay the whole, or any part, of the unpaid principal amount of this Note, without
premium or penalty, provided that interest on the principal amount hereof to be so prepaid accrued to the date of such prepayment
shall be paid concurrently therewith and subject to exercise (at any time prior to the date fixed for prepayment) of the Conversion
Rights contained in Section 7 hereof. Notices of prepayment shall be given by the Maker by mail and shall be mailed to the holder
of this Note not less than 30 days from the date fixed for prepayment. In case this Note is to be prepaid in part only, such notice
shall specify the principal amount hereof to be prepaid. Upon giving of notice of prepayment as aforesaid, this Note or portion
hereof so specified for prepayment shall on the prepayment date specified in such notice become due and payable, and from and
after the prepayment date so specified (unless the Maker shall default in making such prepayment) interest on the principal of
this Note or portion hereof so specified for prepayment shall cease to accrue, and the principal of this Note or portion hereof
so specified for prepayment shall be paid by the Maker at the prepayment price aforesaid.

 

SECTION
4. General Covenants. The Maker covenants and agrees
with the holder of this Note as follows:

 

4.1
The Maker shall punctually pay or cause to be paid the principal of and interest on this Note according to the terms hereof.

 

4.2
The Maker shall and shall cause each Subsidiary to:

 

(a)
pay and discharge promptly, or cause to be paid and discharged promptly all taxes, assessments and governmental charges or levies
imposed upon it or upon its income or upon any of its property, real, personal or mixed, or upon any part thereof, as well as
all claims of any kind (including claims for labor, materials and supplies which, if unpaid, might by law become a lien or charge
upon its property), provided, however, that neither the Maker nor any Subsidiary shall be required to pay any such tax, assessment,
charge, levy or claim if the amount, applicability or validity thereof shall currently be contested in good faith by appropriate
proceedings and if the Maker or such Subsidiary shall have set aside on its books reserves (segregated to the extent required
by sound accounting practice) reasonably deemed by it adequate with respect thereto;

 

(b)
except as otherwise specifically permitted in this Note and as contemplated by Section 5 hereof, do or cause to be done all things
necessary or appropriate to preserve and keep in full force and effect its corporate existence, rights and franchises, and use
its best efforts to qualify as a foreign Maker entitled to do business in every jurisdiction in which the failure so to qualify
would materially adversely effect on its business or properties;

 

    	3

    	 

    

  

(c)
comply in all material respects with all applicable federal, state, county and municipal laws, ordinances, rules, and regulations
now in force or hereafter enacted; and

 

(d)
maintain its books, accounts and records in accordance with generally accepted accounting principles and permit any person or
entity designated by reasonable, advance notice from the holder of this Note to visit and inspect at reasonable hours any of its
properties, books and financial records, and to make copies thereof and take extracts therefrom.

 

4.3
The Maker shall give prompt written notice to the holder of this Note after any officer of the Maker knows or has reason to know
that: (a) a default or an Event of Default hereunder, or any condition, event or act which with the giving of notice or the
passage or lapse of time, or both, would constitute such an Event of Default, has occurred and is continuing, together with a
specification of the same and the steps if any being taken to remedy the same; or (b) any other circumstance or event would
have a material adverse effect on the Maker’s business, properties, operations, income, assets, prospects or condition,
financial or otherwise.

 

SECTION
5. Consolidation Merger or Disposition of Assets.
The Maker shall not consolidate with, merge into, or sell or otherwise dispose of all or substantially all its properties as an
entirety to, any person unless:

 

(a)
the successor formed by or resulting from such consolidation or merger or to which such sale or other disposition shall have been
made shall be a Maker organized under the laws of the United States of America or any State, district or territory thereof;

 

(b)
such successor Maker shall expressly assume the due and punctual payment of the principal of and interest on this Note according
to its tenor, and the due and punctual performance and observance of all the covenants, agreements and conditions of this Note
to be performed or observed by the Maker to the same extent as if such successor Maker had been the original maker of this Note
(and such assumption shall, upon the request of the holder of this Note, be evidenced by the endorsing of an appropriate legend
upon this Note, and any Note executed pursuant to Section 8 hereof after such assumption shall, unless executed in the name of
such Maker, have a similar legend endorsed thereon); and

 

(c)
immediately after such consolidation, merger, sale or other disposition, such successor Maker shall not be in default in the performance
of any of the covenants, agreements or conditions contained in this Note and no condition, act or event (with the giving of notice,
passage of time, or otherwise) would result in such default.

 

    	4

    	 

    

  

SECTION
6. Events of Default and Remedies.

 

6.1
The entire unpaid principal amount of this Note, together with all accrued interest hereon, at the option of the holder hereof
exercised by written notice to the Maker, shall forthwith become and be due and payable if any one or more of the following events
(herein called “Events of Default”) shall have occurred (for any reason whatsoever and whether such happening
shall be voluntary or involuntary or come about or be effected by operation of law or pursuant to or in compliance with any judgment,
decree or order of any court or any order, rule or regulation of any administrative or governmental body) and be continuing at
the time of such notice, that is to say:

 

(a)
if default shall be made in the due and punctual payment of the principal of this Note when and as the same shall become due and
payable, whether at maturity, by acceleration or otherwise, and such default shall have continued for a period of ten days;

 

(b)
if default shall be made in the due and punctual payment of any interest on this Note when and as such interest shall become due
and payable, and such default shall have continued for a period of ten days;

 

(c)
if default shall be made in the performance or observance of any covenant, agreement or condition contained in Section 5
or Section 7.6 hereof;

 

(d)
if default shall be made in the performance or observance of any of the other covenants, agreements or conditions of the Maker
or any Subsidiary contained in this Note or in the Purchase Agreement, and such default shall have continued for a period of 30
days;

 

(e)
if any representation or warranty made by the Maker under the Purchase Agreement or in any document or certificate furnished by
the Maker pursuant thereto shall prove to be inaccurate in any material respect when made;

 

(f)
if this Note or the Purchase Agreement shall cease to be enforceable in accordance with its terms against the Maker, or the Maker
shall so state in writing;

 

(g)
if the Maker or any Subsidiary shall default beyond any period of grace provided with respect thereto in the payment of principal
of, premium, if any, or interest on any obligation in respect of borrowed money when due, whether by acceleration or otherwise;
or if the Maker or any Subsidiary shall default in the performance or observance of any other agreement, term or condition contained
in such obligation or in any agreement under which any such obligation is created, if the effect of any such default is to cause
the holder or holders of such obligations (or a trustee on behalf of such holder or holders) to cause such obligation to become
due prior to the date of its stated maturity, unless such holder or holders or trustee shall have waived such default after its
occurrence or unless such holder or holders or trustee shall have failed to give any notice required to create an event of default
thereunder;

 

(h)
if final judgment for the payment of money shall be rendered by a court of record against the Maker or any Subsidiary and the
Maker or such Subsidiary shall not discharge the same or provide for its discharge in accordance with its terms, or shall not
procure a stay of execution thereon within 30 days from the date of entry thereof and, within the period during which execution
of such judgment shall have been stayed, appeal therefrom, and cause the execution thereof to be stayed during such appeal;

 

    	5

    	 

    

  

(i)
if the Maker or any Subsidiary shall: (i) admit in writing its inability to pay its debts generally as they become due; (ii) file
a petition in bankruptcy or a petition to take advantage of any insolvency act; (iii) make an assignment for the benefit
of creditors; (iv) consent to the appointment of a receiver of itself or of the whole or any substantial part of its property;
(v) on a petition in bankruptcy filed against it, be adjudicated a bankrupt; or (vi) file a petition or answer seeking
reorganization or arrangement under the Federal bankruptcy laws or any other applicable law or statute of the United States of
America or any State, district or territory thereof;

 

(j)
if a court of competent jurisdiction shall enter, except at the direct or indirect request of the holder of this Note, an order,
judgment, or decree appointing, without the consent of the Maker or any Subsidiary, a receiver of the Maker or any Subsidiary
or of the whole or any substantial part of its property, or approving a petition filed against it seeking reorganization or arrangement
of the Maker or any Subsidiary under the Federal bankruptcy laws or any other applicable law or statute of the United States of
America or any State, district or territory thereof, and such order, judgment or decree shall not be vacated or set aside or stayed
within 60 days from the date of entry thereof; or

 

(k)
if, under the provisions of any other law for the relief or aid of debtors, any court of competent jurisdiction shall assume custody
or control of the Maker or any Subsidiary or of the whole or any substantial part of its property and such custody or control
shall not be terminated or stayed within 60 days from the date of assumption of such custody or control.

 

6.2
In the case any one or more of the Events of Default specified in Section 6.1 hereof shall have occurred and be continuing,
the holder of this Note may proceed to protect and enforce its rights either by suit in equity and/or by action at law, whether
for the specific performance of any covenant or agreement contained in this Note, or the holder of this Note may proceed to enforce
the payment of all sums due upon this Note or to enforce any other legal or equitable right of the holder of this Note. In the
event an Event of Default shall have occurred and the holder of this Note shall employ attorneys, or incur other costs and expenses
for the collection of payments due or to become due, or for the enforcement or performance or observance of any obligation or
agreement of the Maker under this Note, the Maker agrees that it will pay to the holder, on demand, the reasonable fees of such
attorney together with all other costs and expenses incurred by the holder.

 

    	6

    	 

    

  

6.3
No remedy herein conferred upon the holder is intended to be exclusive of any other remedy and each and every such remedy shall
be cumulative and shall be in addition to every other remedy given hereunder or now or hereafter existing at law or in equity
or by statute or otherwise.

 

6.4
No course of dealing between the Maker and the holder or any delay on the part of the holder hereof in exercising any rights hereunder
shall operate as a waiver of any rights of the holder hereof.

 

SECTION
7. Conversion. The holder of this Note shall have
conversion rights as follows (the “Conversion Rights”):

 

7.1
Permissive and Mandatory Conversion. The entire outstanding principal amount of this Note, and all accrued and unpaid
interest hereon, or any portion thereof, may be convertible to Common Stock in Maker at any time upon the request of Holder, in
the manner set forth in Section 7.2. Further, to the extent not previously converted to Common Stock in Maker at the request of
Holder: (i) fifty-percent (50%) of the face value of this Note, plus fifty-percent (50%) of all accrued and unpaid interest hereon,
shall be converted to Common Stock in Maker upon the Next Equity Financing; and (ii) all remaining value in this Note, plus all
remaining accrued and unpaid interest hereon, shall be converted to Common Stock in Maker, following the Next Equity Financing,
upon the consummation of Maker’s initial public offering. The number of shares of Common Stock issued upon such conversion
shall be determined by dividing the amount to be converted by the conversion price, determined as hereafter provided, in effect
on the date of such partial or complete conversion (“Conversion Price”). Upon any conversion of this Note,
or any portion hereof, appropriate cash adjustment shall be made for or on account of any interest accrued up to the date of conversion,
or for or on account of any dividends on any shares of Common Stock issued upon such conversion. The initial Conversion Price
shall be $1.00. Such initial Conversion Price shall be subject to adjustment as hereinafter provided.

 

7.2
Mechanics of Conversion. Upon the occurrence of any of the enumerated events set forth in the Section 7.1, the holder
of this Note shall surrender this Note (accompanied, if requested by the Maker, by a duly executed instrument of transfer), at
the office of the Maker, and shall state in writing the name or names in which the certificate or certificates for shares of Common
Stock are to be issued. The Maker shall, as soon as practicable thereafter, issue and deliver at such office to such holder, or
to the nominee or nominees of such holder, a certificate or certificates for the number of shares of Common Stock to which such
holder shall be entitled as aforesaid; and in the event of conversion of only a part of the amount outstanding hereon, the Maker
shall execute and deliver to or on the order of the holder hereof at said office, at the expense of the Maker, a new note (“New
Note”) in an amount equal to the unconverted portion hereof, which New Note shall be dated and bear interest from the
date to which interest shall have been paid on such converted portion. Such conversion shall be deemed to have been made immediately
prior to the close of business on (i) the date of such surrender of this Note as aforesaid, and the person or persons entitled
to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or
holders of such shares of Common Stock as of such date. If the conversion is in connection with an underwritten public offering
of securities registered pursuant to the Securities Act, the conversion may, at the option of any holder hereof, be conditioned
upon the closing with the underwriters of the sale of securities pursuant to such offering, in which event any persons entitled
to receive Common Stock upon conversion of this Note, shall not be deemed to have converted this Note, or portion hereof, until
immediately prior to the closing of such sale of securities.

 

    	7

    	 

    

  

7.3
Conversion Price Adjustments for Certain Splits and Combinations. The Conversion Price shall be subject to adjustment
form time to time as follows: 

 

(a)
Stock Splits and Dividends. In the event the Maker should at any time after the Issuance Date fix a record date
for the effectuation of a split or subdivision of the outstanding shares of Common Stock or the determination of holders of Common
Stock entitled to receive a dividend or other distribution payable in additional shares of Common Stock or Options or Convertible
Securities entitling the holder thereof to receive directly or indirectly, additional shares of Common Stock without payment of
any consideration by such holder for the additional shares of Common Stock, Options or Convertible Securities (including the additional
shares of Common Stock issuable upon conversion or exercise thereof), then, as of such record date (or the date of such dividend
distribution, split or subdivision if no record date is fixed), the Conversion Price shall be appropriately decreased so that
the number of shares of Common Stock issuable on conversion hereof shall be increased in proportion to such increase of the aggregate
of shares of Common Stock outstanding and those issuable with respect to such Options or Convertible Securities with the number
of shares issuable with respect to Options or Convertible Securities determined from time to time as provided in Section 7.3(c)
below.

 

(b)
Reverse Stock Splits. If the number of shares of Common Stock outstanding at any time after the Issuance Date is
decreased by a combination of the outstanding shares of Common Stock, then, following the record date of such combination, the
Conversion Price shall be appropriately increased so that the number of shares of Common Stock issuable on conversion hereof shall
be decreased in proportion to such decrease in outstanding shares.

 

(c)
The following provisions shall apply for purposes of this Section 7.3:

 

(i)
The aggregate maximum number of shares of Common Stock deliverable upon conversion, exchange or exercise of any Options or Convertible
Securities (assuming the satisfaction of any conditions to convertibility, exchangeability or exercisability, including, without
limitation, the passage of time, but without taking into account potential anti-dilution adjustments) shall be deemed to have
been issued at the time such Options or Convertible Securities were issued.

 

    	8

    	 

    

  

(ii)
In the event of any change in the number of shares of Common Stock deliverable or in the consideration payable to the Maker upon
conversion or exercise of such Options or Convertible Securities including, but not limited to, a change resulting from the anti-dilution
provisions thereof, the Conversion Price, to the extent in any way affected by or computed using such Options or Convertible Securities,
shall be recomputed to reflect such change, but no further adjustment shall be made for the actual issuance of Common Stock or
any payment of such consideration upon the conversion, exchange or exercise of such Options or Convertible Securities.

 

(iii)
Upon the termination or expiration of the convertibility, exchangeability or exercisability of any such Options or Convertible
Securities, the Conversion Price, to the extent in any way affected by or computed using such Options or Convertible Securities,
shall be recomputed to reflect the issuance of only the number of shares of Common Stock (and Options or Convertible Securities
which remain convertible, exchangeable or exercisable) actually issued upon the conversion, exchange or exercise of such Options
or Convertible Securities.

 

7.4
Other Distributions. While this Note is outstanding, unless waived by the holder hereof the Maker shall not declare
a distribution (other than a subdivision, combination or merger or sale of assets transaction provided for elsewhere in this Section 7)
on the Common Stock payable in securities of other persons, evidences of indebtedness issued by the Maker or other persons, assets
(excluding cash dividends) or options or rights not referred to in Section 7.3(a). 

 

7.5
Conversion Price Adjustments for Certain Issuance of Securities. Notwithstanding anything to the contrary herein,
the provisions of this Section 7.5 shall neither apply to nor be triggered by the Merger.

 

(a)
If and whenever after the Issuance Date, the Maker shall issue or sell any shares of its Common Stock for a consideration per
share less than the Conversion Price in effect immediately prior to the time of such issue or sale, or without consideration,
then, forthwith upon each such issue or sale, the Conversion Price shall be reduced to the price equal to the consideration per
share in such issuance or sale. In addition, the provisions of this paragraph (a) shall not apply to the issuance of any Excluded
Shares. For purposes hereof, “Excluded Shares” shall refer to any issuances of shares of Common Stock (or options
therefor) from time to time to employees, consultants, service providers, vendors and directors of the Maker directly or pursuant
to stock option plans authorized by the Board of Directors of the Maker.

 

    	9

    	 

    

 

(b)
For purposes of this Section 7.5 the following additional clauses shall apply:

 

(i)
Issuance of Rights or Options. In case at any time the Maker shall in any manner grant (whether directly or by assumption
in a merger or otherwise) any rights to subscribe for or to purchase, or any options for the purchase of, Common Stock or any
stock or securities convertible into or exchangeable for Common Stock (such rights or options being herein called “Options”
and such convertible or exchangeable stock or securities being herein called “Convertible Securities”) whether
or not such Options or the right to convert or exchange any such Convertible Securities are immediately exercisable, and the price
per share for which Common Stock is issuable upon the exercise of such Options or upon the conversion or exchange of such Convertible
Securities (determined by dividing (x) the total amount, if any, received or receivable by the Maker as consideration for
the granting of such Options, plus the aggregate amount of additional consideration payable to the Maker upon the exercise of
all such Options, plus, in the case of such Options which relate to Convertible Securities, the aggregate amount of additional
consideration, if any, payable upon the issue or sale of such Convertible Securities and upon the conversion or exchange thereof,
by (y) the total maximum number of shares of Common Stock issuable upon the exercise of such Options or upon the conversion
or exchange of all such Convertible Securities issuable upon the exercise of such Options) shall be less than the Conversion Price
in effect immediately prior to the time of the granting of such Options, then the total maximum number of shares of Common Stock
issuable upon the exercise of such Options or upon conversion or exchange of the total maximum amount of such Convertible Securities
issuable upon the exercise of such Options shall be deemed to have been issued for such price per share as of the date of granting
of such Options and thereafter shall be deemed to be outstanding. Except as otherwise provided in sub-paragraph (iii) of
this paragraph (b), no adjustment of the Conversion Price shall be made upon the actual issue of such Common Stock or of
such Convertible Securities upon exercise of such Options or upon the actual issue of such Common Stock upon conversion or exchange
of such Convertible Securities.

 

(ii)
Issuance of Convertible Securities. In case the Maker shall in any manner issue (whether directly or by assumption
in a merger or otherwise) or sell any Convertible Securities, whether or not the rights to exchange or convert any such Convertible
Securities are immediately exercisable, and the price per share for which Common Stock is issuable upon such conversion or exchange
(determined by dividing (x) the total amount received or receivable by the Maker as consideration for the issue or sale of
such Convertible Securities, plus the aggregate amount of additional consideration, if any, payable to the Maker upon the conversion
or exchange thereof, by (y) the total maximum number of shares of Common Stock issuable upon the conversion or exchange of
all such Convertible Securities) shall be less than the Conversion Price in effect immediately prior to the time of such issue
or sale, then the total maximum number of shares of Common Stock issuable upon conversion or exchange of all such Convertible
Securities shall be deemed to have been issued for such price per share as of the date of the issue or sale of such Convertible
Securities and thereafter shall be deemed to be outstanding, provided that (I) except as otherwise provided in sub-paragraph
(iii) of paragraph (b), no adjustment of the Conversion Price shall be made upon the actual issue of such Common Stock
upon conversion or exchange of such Convertible Securities, and (II) if any such issue or sale of such Convertible Securities
is made upon exercises of any Options to purchase any such Convertible Securities for which adjustments of the Conversion Price
have been or are to be made pursuant to other provisions of this sub-paragraph (ii), no further adjustment of the Conversion
Price shall be made by reason of such issue or sale.

 

    	10

    	 

    

 

(iii)
Change in Option Price or Exercise Rate. Upon the happening of any of the following events, namely, if the purchase
price provided for in any Option referred to in sub-paragraph (i) of this paragraph (b), the additional consideration,
if any, payable upon the conversion or exchange of any Convertible Securities referred to in sub-paragraphs (i) or (ii) of
this paragraph (b), or the rate at which any Convertible Securities referred to in paragraph (a) of this Section 7.5
are convertible into or exchangeable for Common Stock shall change at any time (other than under or by reason of provisions designed
to protect against dilution), the Conversion Price in effect at the time of such event shall forthwith be readjusted to the Conversion
Price which would have been in effect at such time had such Options or Convertible Securities still outstanding provided for such
changed purchase price, additional consideration or conversion rate, as the case may be, at the time initially granted, issued
or sold; and on the expiration of any such Option or the termination of any such right to convert or exchange such Convertible
Securities, the Conversion Price then in effect hereunder shall forthwith be increased to the Conversion Price which would have
been in effect at the time of such expiration or termination had such Option or Convertible Securities, to the extent outstanding
immediately prior to such expiration or termination, never been issued, and the Common Stock issuable thereunder shall no longer
be deemed to be outstanding. If the purchase price provided for in any such Option referred to in sub-paragraph (i) of this
paragraph (b) or the rate at which any Convertible Securities referred to in sub-paragraph (i) or (ii) of this paragraph (b)
are convertible into or exchangeable for Common Stock shall be reduced at any time under or by reason of provisions with respect
thereto designed to protect against dilution, then, in case of the delivery of Common Stock upon the exercise of any such Option
or upon conversion or exchange of any such Convertible Securities, the Conversion Price then in effect hereunder shall forthwith
be adjusted to such respective amount as would have been obtained had such Option or Convertible Securities never been issued
as to such Common Stock and had adjustments been made upon the issuance of the shares of Common Stock delivered as aforesaid,
but only if as a result of such adjustment the Conversion Price then in effect hereunder is thereby reduced.

 

    	11

    	 

    

 

7.6
Recapitalizations. If at any time or from time to time there shall be a recapitalization or reclassification of
the Common Stock (other than a subdivision, combination or merger or sale of assets transaction provided for elsewhere in this
Section 7) provision shall be made so that the holder of this Note shall thereafter be entitled to receive upon conversion
hereof, the number of shares of stock or other securities or property of the Maker or otherwise, to which a holder of Common Stock
deliverable upon conversion would have been entitled on such recapitalization or reclassification. In any such case, appropriate
adjustment shall be made in the application of the provisions of this Section 7 with respect to the rights of the holder of this
Note after the recapitalization or reclassification to the end that the provisions of this Section 7 (including adjustment
of the Conversion Price then in effect and the number of shares purchasable upon conversion hereof) shall be applicable after
that event and be as nearly equivalent as practicable.

 

7.7
No Impairment. The Maker will not, through any reorganization, recapitalization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder by the Maker, but will at all times in good faith assist in the carrying
out of all the provisions of this Section 7 and in the taking of all such action as may be necessary or appropriate in order
to protect the Conversion Rights of the holder of this Note against impairment.

 

7.8
No Fractional Shares and Certificate as to Adjustments.

 

(a)
No fractional shares shall be issued upon the conversion of this Note. In lieu of fractional shares, the Maker will pay cash in
an amount equal to the fair value of such fractional shares, based on the fair market value of the shares of Common Stock, as
determined in good faith by the Board of Directors, as of the time when those who would otherwise be entitled to receive such
fractional shares is determined. The number of shares issuable upon such conversion shall be determined on the basis of the total
amount hereof, the holder is at the time converting into Common Stock and the number of shares of Common Stock issuable upon such
aggregate conversion.

 

(b)
Upon the occurrence of each adjustment or readjustment of the Conversion Price pursuant to this Section 7, the Maker, at its expense,
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish to each holder
of this Note a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment
or readjustment is based. In the event of a Next Equity Financing a notice of adjustment as aforesaid of the Conversion Price
then to be effective shall be delivered no later than 30 days prior to such event. The Maker shall, upon the written request at
any time of any holder of this Note furnish or cause to be furnished to such holder a like certificate setting forth (i) such
adjustment and readjustment, (ii) the Conversion Price at the time in effect, and (iii) the number of shares of Common
Stock and the amount, if any, of other property which at the time would be received upon the conversion hereof.

 

    	12

    	 

    

 

7.9
Notices of Record Date. In the event of any taking by the Maker of a record of the holders of any class of securities
for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend) or other
distribution, any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities
or property, or to receive any other right, the Maker shall mail to the holder of this Note at least 10 days prior to the date
specified therein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend, distribution
or right, and the amount and character of such dividend, distribution or right.

 

7.10
Reservation of Stock Issuable Upon Conversion. The Maker shall at all times reserve and keep available out of its
authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of this Note, such number of
its shares of Common Stock as shall from time to time be sufficient to effect the conversion of all amounts outstanding on this
Note; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion
of all amounts outstanding on this Note, in addition to such other remedies as shall be available to the holder of this Note,
the Maker will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued
shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging
in best efforts to obtain the requisite shareholder approval of any necessary amendment to the Maker’s certificate of incorporation.

 

7.11
Notices. Any notice required by the provisions of this Section 7 to be given to the holder of this Note shall be
deemed given if deposited in the United States mail, postage prepaid, and addressed to such holder at his address appearing on
the books of the Maker. In case at any time:

 

(a)
the Maker shall declare to the holders of its shares of Common Stock any cash dividend at a rate in excess of the rate of the
last cash dividend theretofore paid;

 

(b)
the Maker shall declare any dividend upon its shares of Common Stock payable in stock or make any special dividend or other distribution
(other than a cash dividend to the holders of its shares of Common Stock);

 

(c)
the Maker shall offer for subscription pro rata to the holders of its shares of Common Stock any additional shares of stock of
any class or other rights;

 

(d)
there shall be a recapitalization or reclassification of the Common Stock; or

 

(e)
there shall be a Next Equity Financing;

 

    	13

    	 

    

 

then,
in any one or more of said cases, the Maker shall give written notice to each holder of this Note of the date on which (A) the
books of the Maker shall close or a record shall be taken for such dividend, distribution or subscription rights, or (B) such
reclassification or recapitalization; or Next Equity Financing, shall take place, as the case may be. Such notice shall also specify
the date as of which the holders of shares of Common Stock of record shall participate in such dividend, distribution or subscription
rights or shall be entitled to exchange their shares of Common Stock for securities or other property deliverable upon such recapitalization
or reclassification, as the case may be. Such written notice shall be given at least 30 days prior to the action in question and
not less than 30 days prior to the record date or the date on which the Maker’s transfer books are closed in respect thereto.

 

7.12
Taxes. The issuance of certificates of shares of Common Stock upon the conversion of this Note shall be made without
charge to the holder thereof for any issuance tax in respect thereto; provided, however, that the Maker shall not be required
to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name
other than that of the holder of this Note.

 

7.13
Closing of Books. The Maker will at no time close its transfer books against the transfer of any shares of Common
Stock issued or issuable upon the conversion of this Note in any manner which interferes with the timely conversion of this Note.

 

SECTION
8. Exchange or Replacement of Note.

 

8.1
The holder of this Note, at its option, may in person or by duly authorized attorney surrender this Note for exchange, at the
principal executive offices of the Maker, and at the expense of the Maker receive in exchange therefor a new Note in the same
aggregate principal amount as the aggregate unpaid principal amount of the Note so surrendered, bearing interest at the same annual
rate as the Note so surrendered and otherwise in substantially the form of the Note so surrendered, each such new Note to be dated
as of the date to which interest has been paid on the note so surrendered and to be in such principal amount and payable to the
holder of this Note. Five days’ prior written notice of the holders intention to make such exchange shall be given to the
Maker.

 

8.2
Upon receipt by the Maker of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Note, and (in case
of loss, theft or destruction) of indemnity reasonably satisfactory to it, and upon surrender and cancellation of this Note, if
mutilated, the Maker, upon reimbursement to it of all reasonable expenses incidental thereto, will make and deliver a new Note,
of like tenor, in lieu of this Note. Any Note made and delivered in accordance with the provisions of this Section 8 shall be
dated as of the date to which interest has been paid on this Note.

 

    	14

    	 

    

 

SECTION
9. Notices. All notices, requests or instructions
hereunder shall be in writing and delivered personally or sent by registered or certified mail, postage prepaid as follows:

 

	 	(1)	if
    to the Maker:
	 	 	 
	 	 	Bone
    Biologics, Corp.
	 	 	175
    May Street, Suite 400
	 	 	Edison,
    NJ 08837
	 	 	Attn:
    Chief Financial Officer
	 	 	 
	 	(2)	if
    to the holder of this Note:
	 	 	 
	 	 	Musculoskeletal
    Transplant Foundation, Inc.
	 	 	125
    May Street, Suite 300
	 	 	Edison,
    New Jersey 08837
	 	 	Attn:
    Chief Financial Officer

 

Any
of the above addresses may be changed at any time by notice given as provided above; provided, however, that any such notice of
change of address shall be effective only upon receipt.

 

SECTION
10. Captions. Captions and section titles contained
herein are inserted as a matter of convenience and for reference only and are not intended to define, limit, extend or describe
the scope of this Note or the intent of any provision hereof.

 

SECTION
11. Severability. In the event that one or more of
the provisions of this Note shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability shall not affect any other provisions of this Note, but this Note shall be construed as if such
invalid, illegal or unenforceable provision had never been contained herein.

 

SECTION
12. Governing Law. This Note shall be governed by
and construed in accordance with the laws of the State of Delaware applicable to agreements made and to be performed entirely
within such state.

 

SECTION
13. Related Agreements. This Note is issued pursuant
to the Purchase Agreement and is entitled to the benefits thereof. Copies of such agreement may be obtained by any holder of this
Note at the principal executive offices of the Maker.

 

[Signature
Page Follows]

 

    	15

    	 

    

 

IN
WITNESS WHEREOF, the undersigned has executed this Note as of the date first above written.

 

	ATTEST:	 	BONE
    BIOLOGICS, CORP.
	 	 	 	 	 
	By:	/s/
    Deina     H. Walsh	 	By:	/s/
    William     Jay Treat
	Name:	Deina
    H. Walsh	 	Name:	William
    Jay Treat
	Title:	Witness	 	Title:	President
    and Chief Technology Officer

 

[Signature
Page to Convertible Promissory Note]PROMISSORY
NOTE

(Secured)

 

	$340,000.00	July
    31, 2014

 

For
value received, the undersigned, Bone Biologics, Inc., a California
corporation (the “Company”), hereby promises to pay to AFH Holding and Advisory, LLC (“AFH”),
at 4751 Wilshire Blvd., Suite 110, Los Angeles, CA 90010, or any other place designated in a writing submitted by AFH to the Company,
the principal sum of Three-Hundred Forty Thousand Dollars and 00/100 ($340,000.00), together with interest thereon, as calculated
below. All sums owing under this Promissory Note (this “Note”) are payable in lawful money of the United
States of America, in immediately available funds.

 

1.
Interest. Interest on all sums owing on this Note shall accrue at a rate of eight and one-half percent (8.5%) per annum,
commencing ninety days after the Effective Date and continuing until the Maturity Date, and at a rate of eight and one-half percent
(8.5%) per annum, commencing on the Maturity Date and continuing until this Note is paid in full, based on a three hundred sixty
(360) day year and charged on the basis of actual days elapsed.

 

2.
Payment. The Company shall make payments of principal to AFH commencing on the Initial Date. Payments of principal
by the Company to AFH shall be made as follows: $250,000.00 contemporaneous with the Company closing on a total of $1,500,000.00
in the Offering (the “Initial Date”); and $90,000.00 contemporaneous with the Company closing on a total
of $2,040,000.00 in the Offering. For purposes of this Note, the term “Offering” shall mean that certain
upcoming offering pursuant to which the Company will be selling between $1,000,000.00 and $5,000,000.00 worth of its $0.001 par
value per share common stock to investors. Payments to third-parties out of the proceeds of the Offering shall be made in accordance
with the terms of that certain Amended and Restated Letter of Intent, dated May 7, 2014, by and among the Company, the Musculoskeletal
Transplant Foundation, Inc., a District of Columbia Corporation (“MTF”), and AFH.

 

3.
Maturity Date. If not already due and payable in accordance with the terms of Section 2, the outstanding principal
balance shall be due and payable in full six (6) months after the Effective Date (the “Maturity Date”);
provided, however, that the Company may pay all or any portion of such outstanding principal at any time before such date without
penalty.

 

4.
Late Fee. If any installment is not received by AFH within ten (10) Business Days of being due, the Company will pay
a late fee of five percent (5%) of the overdue amount as a late fee. Acceptance of any late fee shall not constitute a waiver
of default with respect to the overdue amount, and such late fee shall be paid by the Company in addition to any other costs,
attorneys’ fees, and remedies to which AFH may be entitled as a result of an Event of Default under this Note.

 

    	 

    	 

    

 

5.
Events of Default. At the option of AFH, the entire unpaid principal amount of this Note and any accrued interest thereon
shall become immediately due and payable if an Event of Default shall occur. Each of the following events shall constitute an
Event of Default hereunder:

 

a.
The failure to pay when due the amount of any interest or principal payment required to be paid hereunder, which failure continues
for thirty (30) days after the Company receives written notice of such nonpayment;

 

b.
A petition or action for relief shall be filed by or against the Company, pursuant to the Federal Bankruptcy Code (Title 11,
U.S. Codes) in effect from time to time, or under any other law relating to bankruptcy, insolvency, reorganization, moratorium,
creditor composition, arrangement or other relief from debts; the appointment of a receiver, trustee, custodian or liquidator
of or for any property of the Company; or upon the insolvency, dissolution, or termination of the business of the Company;

 

c.
The Company shall (i) admit in writing its inability to pay its debts generally as they mature; (ii) make an assignment for
the benefit of creditors or commence proceedings for its dissolution; or (iii) apply for or consent to the appointment of a trustee,
liquidator or receiver for its or for a substantial part of its property or business;

 

d.
Any governmental agency or any court of competent jurisdiction at the instance of any governmental agency shall assume custody
or control of the whole or any substantial portion of the properties or assets of the Company; and

 

e.
The Company fails to comply with any covenant, condition or provision contained in this Note or materially breaches any provision
hereof, and such failure continues or such breach is not corrected within thirty (30) days after the Company receives written
notice of such failure or such breach.

 

6.
Attorneys’ Fees. If any attorney is engaged by AFH to enforce or defend any provision of this Note, or as a consequence
of any default hereunder, with or without the filing of any legal action or proceeding, then the Company shall pay to AFH immediately
upon demand all attorneys’ fees and all costs incurred by AFH in connection therewith, together with interest thereon from
the date of such demand until paid at the rate of interest applicable to the principal balance owing hereunder as if such unpaid
attorneys’ fees and costs had been added to the principal.

 

7.
Waiver. AFH’s acceptance of partial or delinquent payment from the Company, or AFH’s failure or delay in
exercising any right hereunder, shall not constitute a waiver of any obligation of the Company hereunder, or any right of AFH
hereunder, and shall not affect in any way the right to require full performance at any time thereafter. Any waiver of any term
of this Note and any amendment to this Note must be made in writing and signed by AFH and the Company, and shall in all cases
be limited to the express terms of such waiver or amendment. No previous waiver by AFH with respect to the terms of this Note
shall constitute a waiver of any later breach, default, or failure of any condition under this Note. Except as otherwise provided
in this Note, the Company waives: statutes of limitation; presentment; notice of dishonor; notice of default or delinquency; notice
of acceleration; notice of protest and nonpayment; notice of cost, expenses or losses and interest thereon; notice of late charges;
and diligence in taking any action to collect any sums owing under this Note or in any proceeding against any of the rights or
interests in or to properties securing payment of this Note, if any.

 

    	2

    	 

    

 

8.
Security. As security for payment of this Note, AFH will receive a Standby Letter of Credit from MTF for the full principal
of this Note pursuant to the terms of that certain Agreement, by and among the Company, AFH Acquisition X, Inc. and Bone Biologics
Acquisition Corp. , in the form attached hereto as Exhibit A.

 

9.
Order of Payments. Payments shall be applied first to any fees or other costs owed to AFH in connection with the enforcement
and collection of this Note as provided by this Note, thereafter to the outstanding amount of interest, if any, and thereafter
to the outstanding principal amount.

 

10.
Bank Account Designated by AFH. Payments shall be made by electronic transfer to the bank account designated in writing
by AFH.

 

11.
Transfer of Note. AFH may assign or pledge all or part of its rights under this Note. Whenever in this Note there is
reference made to AFH, such reference shall be deemed to include as applicable, a reference to the respective successors and assigns
of AFH. The provisions of this Note shall be binding upon and shall inure to the benefit of said successors and assigns.

 

12.
General Provisions. This Note is intended by AFH and the Company as the complete and final expression of their
agreement concerning the subject matter herein. It supersedes all prior understandings or agreements with respect thereto and
may be changed only by a writing signed by AFH and the Company. No course of dealing, or parole or extrinsic evidence shall be
used to modify or supplement the express terms of this Note. If any provision of this Note is found to be illegal, invalid, or
unenforceable, such provision shall be enforced to the maximum extent permitted, but if fully unenforceable, such provision shall
be severable, and this Note shall be construed as if such provision had never been a part of this Note, and the remaining provisions
shall continue in full force and effect. The provisions hereof are binding upon the successors of the Company and inure to the
benefit of the successors of AFH. Each right, power, and remedy provided in this Note shall be cumulative and shall be in addition
to every other right, power, and remedy provided in this Note now or hereafter existing at law, in equity or otherwise. The section
and paragraph headings contained in this Note are for reference purposes only and shall not affect in any way the meaning or interpretation
of this Note. The term “Business Day” means any day other than Saturday, Sunday, or a day on which commercial
banks in California or New York are obligated by any legal requirement to close.

 

13.
Governing Law. This Note shall be construed and enforced in accordance with the laws of the State of California, except
to the extent that Federal laws preempt the laws of the State of California, and all persons and entities in any manner obligated
under this Note consent to the jurisdiction and venue of the Federal and State of California courts situated in Los Angeles, California,
and also consent to service of process by any means authorized by California or Federal law.

 

14.
Effective Date. This Note is made effective as of the date first set forth above (the “Effective Date”).

 

[Remainder
of Page Intentionally Left Blank; Signature Page Follows]

 

    	3

    	 

    

  

IN
WITNESS WHEREOF, the undersigned has caused this Note to be duly executed and delivered as of the Effective Date.

 

	 	THE
    COMPANY:   	Bone
    Biologics, Inc.,
	 	 	a
    California corporation
	 	 	 	 
	 	 	By:	/s/
    Michael     Schuler
	 	 	 	Michael
    Schuler, Chief Executive Officer

 

[Signature
Page to Promissory Note]

 

    	 

    	 

    

  

EXHIBIT
A

 

FORM
OF LETTER OF CREDIT

 

    	 

    	 

    

  

 

 

CERTIFIED
TRUE COPY

 

	BANK
    OF AMERICA – CONFIDENTIAL	PAGE:
    1

 

DATE: JULY
25, 2014

 

	IRREVOCABLE
    STANDBY LETTER OF CREDIT NUMBER: 68105133
	 
	 	ISSUING
                                         BANK

        BANK
        OF AMERICA, N.A.

        ONE
        FLEET WAY

        PA6-580-02-30

        SCRANTON,
        PA 18507-1999

	 	 
	BENEFICIARY

        AFH
        HOLDING & ADVISORY, LLC

        AMIR
        F HESHMATPOUR

        CHAIRMAN
        & MANAGING DIRECTOR

        9595
        WILSHIRE BLVD SUITE 700
	APPLICANT

        MUSCULOSKELETAL
        TRANSPLANT

        FOUNDATION,
        INC.

        125
        MAY STREET

        EDISON,
        NJ 08837

	 	 
	BEVERLY
    HILLS, CA 90212	 

 

AMOUNT

NOT EXCEEDING
USD 340,000.00

NOT EXCEEDING
THREE HUNDRED FORTY THOUSAND AND 00/100’S US DOLLARS

 

EXPIRATION

JULY 25,
2015 AT OUR COUNTERS

 

GENTLEMEN:

 

WE HEREBY
OPEN OUR IRREVOCABLE STANDBY LETTER OF CREDIT NUMBER 68105133 IN YOUR FAVOR.

 

THIS CREDIT
IS AVAILABLE WITH BANK OF AMERICA BY PAYMENT AGAINST PRESENTATION OF BENEFICIARY’S DRAFT(S) AT SIGHT DRAWN ON BANK OF AMERICA
N.A.

 

DRAFT(S)
MUST BE ACCOMPANIED BY:

 

	1.	THE
    ORIGINAL LETTER OF CREDIT AND ALL AMENDMENTS, IF ANY.
	 	 
	2.	AN
    AFFIDAVIT SIGNED BY AFH HOLDING AND ADVISORY LLC, CERTIFYING ONE OF THE FOLLOWING:

 

QUOTE

 

A. BONE
BIOLOGICS HAS FAILED TO RECEIVE EXTERNAL FUNDING TO EXTINGUISH THE FULL AMOUNT OF $340,000 OR A PORTION THEREOF STILL OWED UNDER
THE PURCHASE AGREEMENT TO ACQUIRE AFH ACQUISITION X, OR HAS NOT PAID AMOUNTS DUE AND OUTSTANDING. AS OF THE DATE OF THIS DRAWING
SUCH PAYMENT HAS NOT BEEN RECEIVED, AND THEREFORE WE DRAW IN

 

CERTIFIED
TRUE COPY

 

    	 

    	 

    

 

 

 

CERTIFIED
TRUE COPY

 

	BANK
    OF AMERICA – CONFIDENTIAL	PAGE:
    2

 

THIS IS
AN INTEGRAL PART OF LETTER OF CREDIT NUMBER: 68105133

 

THE AMOUNT
OF $___________ OWED BY BONE BILOGICS.

 

UNQUOTE

 

QUOTE

 

B. BONE
BIOLOGICS HAS RECEIVED EXTERNAL FUNDING TO EXTINGUISH THE FULL AMOUNT OF $340,000 OR A PORTION THEREOF STILL OWED UNDER THE PURCHASE
AGREEMENT TO ACQUIRE AFH ACQUISITION X, BUT HAS NOT PAID AMOUNTS DUE AND OUTSTANDING. AS OF THE DATE OF THIS DRAWING SUCH PAYMENT
HAS NOT BEEN RECEIVED, AND THEREFORE WE DRAW IN THE AMOUNT OF $ OWED BY BONE BILOGICS.

UNQUOTE

 

PARTIAL
DRAWINGS AND MULTIPLE DRAWINGS ARE ALLOWED.

 

DRAFT(S)
MUST STATE “DRAWN UNDER BANK OF AMERICA N.A., STANDBY LETTER OF CREDIT NUMBER 68105133 DATED JULY 22, 2015.”

 

DRAFT(S)
AND DOCUMENTS SHALL BE PRESENTED AT OUR OFFICES AT BANK OF AMERICA, N.A. ONE FLEET WAY, PA6-580 - 02-30, SCRANTON, PA 18507-1999,
ATTN: GLOBAL TRADE OPERATIONS, STANDBY UNIT.

 

THIS LETTER
OF CREDIT IS TRANSFERABLE IN FULL AND NOT IN PART. ANY TRANSFER MADE HEREUNDER MUST CONFORM STRICTLY TO THE TERMS HEREOF AND TO
THE CONDITIONS OF RULE 6 OF THE INTERNATIONAL STANDBY PRACTICES (ISP98) FIXED BY THE INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION
NO. 590. SHOULD YOU WISH TO EFFECT A TRANSFER UNDER THIS CREDIT, SUCH TRANSFER WILL BE SUBJECT TO THE RETURN TO US OF THE ORIGINAL
CREDIT INSTRUMENT, ACCOMPANIED BY OUR FORM OF TRANSFER, PROPERLY COMPLETED AND SIGNED BY AN AUTHORIZED SIGNATORY OF YOUR FIRM,
BEARING YOUR BANKERS STAMP AND SIGNATURE AUTHENTICATION AND PAYMENT OF OUR TRANSFER FEE. SUCH TRANSFER FORM TRANSFER FORM IS AVAILABLE
UPON REQUEST.

 

COMMUNICATIONS
WITH RESPECT TO THIS LETTER OF CREDIT SHALL BE IN WRITING AND SHALL BE ADDRESSED TO US AT ONE FLEET WAY, PA6-580 - 02 - 30, SCRANTON,
PA 18507-1999, ATTN: GLOBAL TRADE OPERATIONS, STANDBY UNIT, PHONE: 1-800-370-7519, SPECIFICALLY REFERRING TO THE NUMBER OF THIS
LETTER OF CREDIT.

 

EXCEPT AS
OTHERWISE EXPRESSLY STATED HEREIN, THIS CREDIT IS ISSUED SUBJECT TO THE INTERNATIONAL STANDBY PRACTICES (ISP98), INTERNATIONAL
CHAMBER OF COMMERCE PUBLICATION NO. 590.

 

IF YOU REQUIRE
ANY ASSISTANCE OR HAVE ANY QUESTIONS REGARDING THIS TRANSACTION, PLEASE CALL 800-370-7519 OPT 1 .

 

	 	 
	AUTHORIZED
    SIGNATURE	 

 

THIS
DOCUMENT CONSISTS OF 2  PAGE(S).

 

CERTIFIED
TRUE COPY

 

    	 

    	 

    

 

 

 

	BANK
    OF AMERICA – CONFIDENTIAL	PAGE:
    1
	 	 
	DATE:
    JULY 28, 2014	 
	 	 
	AMENDMENT
    TO IRREVOCABLE STANDBY LETTER OF CREDIT NUMBER: 68105133
	 
	AMENDMENT
    NUMBER 1	 
	 	 
	 	ISSUING
                                         BANK

        BANK
        OF AMERICA, N.A.

        ONE
        FLEET WAY

        PA6-580-02-30

        SCRANTON,
        PA 18507-1999

	 	 
	BENEFICIARY

        AFH
        HOLDING & ADVISORY, LLC

        AMIR
        F HESHMATPOUR

        CHAIRMAN
        & MANAGING DIRECTOR

        10830
        MASSACHUSETTS AVE
	APPLICANT

        MUSCULOSKELETAL
        TRANSPLANT

        FOUNDATION,
        INC.

        125
        MAY STREET

        EDISON,
        NJ 08837

	 	 
	PENTHOUSE
                                         SUITE

        LOS
        ANGELES, CA 90 024
	 

 

 

THIS AMENDMENT
IS TO BE CONSIDERED AN INTEGRAL PART OF THE ABOVE CRED: AND MUST BE ATTACHED THERETO.

 

THE ABOVE
MENTIONED CREDIT IS AMENDED AS FOLLOWS:

 

THE BENEFICIARY
HAS BEEN AMENDED TO:

AFH HOLDING
& ADVISORY, LLC

AMIR F HESHMATPOUR

CHAIRMAN
& MANAGING DIRECTOR

10830 MASSACHUSETTS
AVE

 

PENTHOUSE
SUITE

LOS ANGELES,
CA 90024

 

ALL OTHER
TERMS AND CONDITIONS REMAIN UNCHANGED.

 

IF YOU REQUIRE
ANY ASSISTANCE OR HAVE ANY QUESTIONS REGARDING THIS AMENDMENT, PLEASE CALL 800-370-7519 OPT 1 .

 

	 	 
	AUTHORIZED
    SIGNATURE	 

 

THIS
DOCUMENT CONSISTS OF 1  PAGE(S).

 

ORIGINAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]